UMass Chan Medical School’s Health AI Assurance Laboratory signed a memorandum of understanding with Red Cell Partners, an investment firm and incubator, to develop a variety of artificial intelligence products in the healthcare space.
As part of the two-year agreement, UMass Chan joined Red Cell’s Partners Advancing Critical Technologies program to select AI-driven healthcare products from the firm’s portfolio to test using real-world clinical data. The two organizations aim to identify safe and effective AI tools quickly.
“The partnership with Red Cell is to create a feeder system of AI companies to come to us, establish guidelines on AI assurance on how it is deployed in patient care, and at the same time, to build our business model out to support the industry and determine the turn-around time to make AI startups competitive in healthcare,” said Adrian Zai, MD, PhD, associate professor of population and quantitative health sciences and chief research informatics officer at UMass Chan. He also co-leads the Health AI Assurance laboratory and is the director of data sciences core within the department of population and quantitative health sciences. Dr. Zai also directs the biomedical informatics core at the center for clinical and translational science.
Under the agreement, UMass will get a fee-based reimbursement for data access and services.
“As early and serious market entrants, we have developed great talent, as well as the technical infrastructure, national network, and intramural governance to contribute meaningfully to industry partners like Red Cell,” said David McManus, MD, the Richard M. Haidack Professor in Medicine, chair and professor of medicine and founder of the Health AI Assurance Laboratory.
